JP2003517423A - アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド - Google Patents

アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド

Info

Publication number
JP2003517423A
JP2003517423A JP2000504866A JP2000504866A JP2003517423A JP 2003517423 A JP2003517423 A JP 2003517423A JP 2000504866 A JP2000504866 A JP 2000504866A JP 2000504866 A JP2000504866 A JP 2000504866A JP 2003517423 A JP2003517423 A JP 2003517423A
Authority
JP
Japan
Prior art keywords
adenosine
echiruuronamido
receptor
alkaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000504866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517423A5 (fr
Inventor
バラルディ、ピエル、ジー
Original Assignee
メドコ リサーチ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メドコ リサーチ、インコーポレイテッド filed Critical メドコ リサーチ、インコーポレイテッド
Publication of JP2003517423A publication Critical patent/JP2003517423A/ja
Publication of JP2003517423A5 publication Critical patent/JP2003517423A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2000504866A 1997-07-29 1998-07-29 アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド Pending JP2003517423A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5406497P 1997-07-29 1997-07-29
US60/054,064 1997-07-29
PCT/US1998/016053 WO1999006053A1 (fr) 1997-07-29 1998-07-29 N6-substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Publications (2)

Publication Number Publication Date
JP2003517423A true JP2003517423A (ja) 2003-05-27
JP2003517423A5 JP2003517423A5 (fr) 2006-01-05

Family

ID=21988552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000504866A Pending JP2003517423A (ja) 1997-07-29 1998-07-29 アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド

Country Status (5)

Country Link
EP (1) EP1019427A4 (fr)
JP (1) JP2003517423A (fr)
AU (1) AU8764398A (fr)
CA (1) CA2296485A1 (fr)
WO (1) WO1999006053A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508256A (ja) * 2004-07-28 2008-03-21 キャン−ファイト・バイオファーマ・リミテッド シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289731A1 (fr) * 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
CZ302486B6 (cs) 1998-06-02 2011-06-15 Osi Pharmaceuticals, Inc. N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
KR100840727B1 (ko) 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002035231A1 (fr) * 2000-10-26 2002-05-02 Actar Ab Procede de tri a l'aide d'un recepteur couple a la g associe a une proteine g specifique
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
EP1450811B1 (fr) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Composés specifiques aux recepteurs A1 et A3 de l'adenosine et leur utilisations
EA011809B1 (ru) 2001-12-20 2009-06-30 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
EP1685135B1 (fr) * 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. COMPOSES TETRAHYDRO-FURO[3,4-d]DIOXOLE, ET COMPOSITIONS ET PROCEDE POUR INHIBER UNE AGREGATION PLAQUETTAIRE
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1798233A1 (fr) * 2005-12-19 2007-06-20 Faust Pharmaceuticals Dérivés de Pyrrolo[1,2-a]quinoxaline et leur utilisation comme modulateurs de recepteurs a l'adenosine
EP2227234B1 (fr) 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Procédé pour induire une prolifération d'hépatocytes et ses utilisations
CN102427819A (zh) 2009-05-17 2012-04-25 坎-菲特生物药物有限公司 用于减小眼内压的a3腺苷受体激动剂
EP2456419B1 (fr) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. Ligands du récepteur a3 adenosine pour la modulation de la pigmentation
EP2542242A1 (fr) 2010-03-03 2013-01-09 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Agonistes a3ar dans le cadre du traitement de l'uvéite
EP2892533A1 (fr) 2012-08-09 2015-07-15 Can-Fite Biopharma Ltd. Ligands des recepteurs adenosine a3 pour utilisation dans le traitement d'un dysfonctionnement sexuel
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
CA2289731A1 (fr) * 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508256A (ja) * 2004-07-28 2008-03-21 キャン−ファイト・バイオファーマ・リミテッド シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト

Also Published As

Publication number Publication date
EP1019427A1 (fr) 2000-07-19
EP1019427A4 (fr) 2000-07-19
WO1999006053A1 (fr) 1999-02-11
AU8764398A (en) 1999-02-22
CA2296485A1 (fr) 1999-02-11

Similar Documents

Publication Publication Date Title
JP2003517423A (ja) アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
US6048865A (en) N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
EP0708781B1 (fr) Agonistes du recepteur de l'adenosine a 3
ZA200101626B (en) Adenosine A3 receptor modulators.
JP2001522858A (ja) 化合物
AU2007348394B2 (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
JP2002518511A (ja) ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
EP0920438A2 (fr) Derives d'adenosine a substitution heterocyclique n6
JPS63239294A (ja) 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
JP7175525B2 (ja) アデノシン誘導体を含む非アルコール性脂肪肝炎、肝線維症及び肝硬変症の予防及び治療用薬学的組成物
US6358964B1 (en) Adenosine, A3 receptor modulators
JP2008505967A (ja) Ａ１アデノシンレセプターアゴニストの製造方法
KR20100029002A (ko) 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물
Jacobson Adenosine receptor agonists
EP1368364B1 (fr) Derives d'adenosine disubstitues c2, 8 et leurs diverses utilisations
JP2003502434A (ja) チオフェンａ２ａ受容体アゴニスト
JP2509140B2 (ja) アデノシン誘導体を有効成分として含有する医薬組成物
KR20070046907A (ko) Ａ1 아데노신 수용체의 부분 및 전 아고니스트
KR20070032007A (ko) Ａ1 아데노신 수용체 아고니스트의 제조 방법
CZ20004240A3 (cs) Modulátory adenosinového receptorů A3

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091016